AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma
AbbVie is conducting a study to evaluate the safety and efficacy of surzetoclax in combination with other agents for relapsed/refractory multiple myeloma.
| Drug | MOA / Company | Stage |
|---|---|---|
| daratumumab | AbbVie | Lead |
Focal Asset
daratumumab
Company
AbbVie
Indication
Oncology / Multiple Myeloma
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
AbbVie's trial of surzetoclax could significantly impact its competitive positioning in the multiple myeloma market, particularly against established therapies. Monitoring the trial's progress is crucial as positive outcomes may redefine treatment standards and market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress and initial safety data from the trial, particularly in the dose escalation phases.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.